Novo Nordisk A/S buy OldOrangeEyes
Start price
16.10.22
/
50%
€108.12
Target price
16.10.23
-
Performance (%)
25.06%
End price
03.03.23
€135.22
Summary
This prediction ended on 03.03.23 with a price of €135.22. The BUY prediction by OldOrangeEyes finished with a performance of 25.06%. OldOrangeEyes has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Novo Nordisk A/S | - | - | - |
| iShares Core DAX® | -1.042% | 2.220% | 14.279% |
| iShares Nasdaq 100 | -1.361% | 3.207% | 26.657% |
| iShares Nikkei 225® | -0.044% | -1.680% | 5.941% |
| iShares S&P 500 | -0.480% | 2.165% | 23.067% |